Currently available predictive biomarkers include PD-L1 expression (Havel et al., 2019), tumor-infiltrating lymphocytes (Tumeh et al., 2014), and tumor mutational burden (TMB) (Carbone et al., 2017; McGranahan et al., 2016; Rizvi et al., 2015). This evidence concerns the gene CD274 and neoplasm.